Healthcare group Stirling Products Ltd
(ASX:STI) has received the green light to establish a pharmaceutical plant in Canada.
The pharmaceuticals marketer says its Canadian subsidiary Stirling Pharma has been issued a license to manufacture, test and package natural health products and over-the-counter or prescriptions drugs.
Managing director Peter Boonen says achieving the full licensing of the plant now positions the company to pursue contract manufacturing revenues, and also begin the formulation and production of Stirling branded products.
The manufacturing facility will enable clients to bring their products from the laboratory to the market, with Stirling providing development, scale-up and commercial production expertise.
In the year to 30 June 2010, Stirling Products booked a net loss of $7.87 million.
